Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azithromycin plus standard treatment versus standard treatment alone in COPD
IRCT20210405050849N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of azithromycin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Spirometric parameters, COPD Assessment Test score and 1 more. Started Jun 2021; status: completed.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20210405050849N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210405050849N1.